That would explain why Scienion are named as a "Partner" and ADO is not.
That's frightening in a way. If ADO will only be paid per gram of M&G, rather than a royalty per test, it could significantly reduce return to ADO.
Maybe the SP reflects that?
Then again, if M&G is what makes the test "superior", then we should be able to negotiate a rate comparable to a royalty anyway.
Cheers,
FHC
Phillips News, page-40
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.90M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.8¢ | $14.63K | 773.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 2514072 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 1915345 | 2 |
View Market Depth
| Last trade - 15.57pm 14/08/2024 (20 minute delay) ? |
| ADO (ASX) Chart |